Title |
Update on augmentation of antidepressant response in resistant depression
|
---|---|
Published in |
Current Psychiatry Reports, December 2005
|
DOI | 10.1007/s11920-005-0064-x |
Pubmed ID | |
Authors |
Charles DeBattista, Anna Lembke |
Abstract |
Most patients in acute depression trials fail to achieve remission with antidepressant monotherapy. Many patients seem to require more than one medication to achieve remission or adequate response. Augmentation strategies are commonly used in clinical practice, but most have been poorly studied. In addition, better-studied strategies, such as the use of lithium and thyroid augmentation, have not been well investigated in combination with newer antidepressants. Various novel strategies are being investigated as augmenting agents, including selective dopamine agonists, sex steroids, norepinephrine reuptake inhibitors, glucocorticoid-specific agents, and newer anticonvulsants. We review the status of augmentation strategies in the treatment of depression. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Unknown | 24 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 20% |
Researcher | 4 | 16% |
Student > Doctoral Student | 2 | 8% |
Student > Bachelor | 2 | 8% |
Other | 2 | 8% |
Other | 7 | 28% |
Unknown | 3 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 52% |
Psychology | 4 | 16% |
Agricultural and Biological Sciences | 1 | 4% |
Neuroscience | 1 | 4% |
Chemistry | 1 | 4% |
Other | 0 | 0% |
Unknown | 5 | 20% |